...
首页> 外文期刊>Journal of interventional cardiology >Low-dose protamine to facilitate earlier sheath removal from the femoral artery after peripheral endovascular intervention.
【24h】

Low-dose protamine to facilitate earlier sheath removal from the femoral artery after peripheral endovascular intervention.

机译:小剂量鱼精蛋白有助于外周血管内介入术后较早从股动脉去除鞘。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVES: This study aimed to evaluate the safety of low-dose protamine administration to facilitate earlier vascular sheath removal. BACKGROUND: Vascular access complications are the most common cause of postprocedural morbidity in patients undergoing peripheral endovascular intervention (PEI). Prolonged manual compression and closure devices do not eliminate these complications. METHODS: A consecutive series of 166 patients who underwent PEI were retrospectively compared to an all-comers control group of 136 patients who did not receive protamine. The study population received an intravenous dose of protamine based upon the dose of heparin received and the length of the procedure. The arterial sheath was removed when activated clotting time was less than 220 seconds. Primary end-points included bleeding complications, comprised of groin hematomas and retroperitoneal bleeding, and vascular complications, comprised of pseudoaneurysms, access vessel thrombosis, and arteriovenous fistula formation. RESULTS: The study population on average was older than the control group (71 vs. 67 years) and had a higher incidence of hypercholesterolemia (89.8% vs. 76.5%, P = 0.002). The average dose of protamine was 1.9 +/- 0.83 mg, with a total dose of heparin of 5371 +/- 1327 units. The time until sheath removal was 8.9 +/- 8.6 minutes in the protamine group versus 188 +/- 118 minutes in the control group (P < 0.001). There were no episodes of protamine anaphylaxis or adverse reactions. The access site complication rate between the 2 groups was statistically insignificant. CONCLUSIONS: This strategy offers an inexpensive, safe, and reliable method to achieve hemostasis and facilitate earlier sheath removal in patients undergoing PEI.
机译:目的:本研究旨在评估低剂量鱼精蛋白给药的安全性,以促进早期血管鞘的去除。背景:血管通路并发症是接受外周血管内介入治疗(PEI)的患者术后并发症的最常见原因。长时间的手动压缩和闭合装置无法消除这些并发症。方法:回顾性分析了连续进行的166例接受PEI的患者,与全对照组的136例未接受鱼精蛋白的患者进行比较。根据接受的肝素剂量和手术时间,研究人群接受静脉注射鱼精蛋白。当激活的凝血时间少于220秒时,除去动脉鞘。主要研究终点包括出血并发症,包括腹股沟血肿和腹膜后出血,以及血管并发症,包括假性动脉瘤,通路血管血栓形成和动静脉瘘管形成。结果:研究人群的平均年龄高于对照组(71岁对67岁),高胆固醇血症发生率更高(89.8%对76.5%,P = 0.002)。鱼精蛋白的平均剂量为1.9 +/- 0.83毫克,肝素的总剂量为5371 +/- 1327单位。鱼精蛋白组直至去除鞘的时间为8.9 +/- 8.6分钟,而对照组为188 +/- 118分钟(P <0.001)。没有鱼精蛋白过敏反应或不良反应的发作。两组之间的进入部位并发症发生率在统计学上无关紧要。结论:该策略提供了一种廉价,安全和可靠的方法来实现止血,并有利于在接受PEI的患者中更早地去除护套。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号